Traditional pharmaceutical development is a linear, siloed, and largely manual process, requiring extensive data documentation across fragmented systems, analysis tools, and reporting mechanisms. Scaling a process from the lab to pilot and eventually full commercial production often demands extensive rework and troubleshooting. Most process knowledge is developed late in the lifecycle, with little connection between research and development (R&D) datasets and plant operations. Adding to the complexity, pilot and production equipment may follow different data standards, creating barriers to efficiency and consistency.
Due to the extensive integration and custom engineering required for legacy automation equipment, development processes have often relied heavily on manual steps, with automation introduced only late in Phase 3 — or sometimes rushed in just before process performance qualification. At this stage, automation teams typically have to scramble to build control recipes, integrate equipment, tune and validate systems, and write standard operating procedures. The result is an “automation crunch” that can cause delays, costly rework, and increased expenses.
A proactive approach can prevent these issues. Rather than reacting to unexpected challenges during pilot runs or commercial scale-up, organizations can benefit from planning automation strategies and optimizing parameters early in R&D. Doing so lays the groundwork for smoother transitions across phases, reduces rework, and shortens time to production.
Building a modern, fully integrated R&D-to-production pipeline requires more than incremental fixes. Module Type Package (MTP) is an industry standard that makes it easier to connect equipment to higher-level control systems. It provides a standard description of functions and elements, so teams don’t need custom coding for every machine. Software-controlled automation allows rapid process changes, flexible scaling, and easier adjustments. A unified data system helps track processes, analyze performance, and move smoothly from development to production.
Data is the structural foundation
Pharmaceutical manufacturing is increasingly complex, and emerging modalities are creating new challenges for scaling lab processes to full production. Seamlessly transferring process information from the lab to pilot and production stages helps reduce the scaling risks that have historically caused delays and rework. Manufacturing processes involve many variables — process parameters, equipment states, environmental conditions, and more — and traditional siloed, univariate monitoring makes it difficult to understand how these variables interact, often resulting in an incomplete picture of process behavior. A unified data architecture empowers analytics across the entire process and is essential for deploying machine learning models to detect anomalies or optimize methods.
As development workflows evolve, data structures must support change and feed centralized monitoring for optimization. A data orchestration layer enables rapid integration of information from new instruments or modular process units (known as skids) for analysis. Once data is aggregated and contextualized during development, the challenges of siloed data during scale-up are greatly reduced. This early visibility allows identification of critical process parameters and critical material attributes sooner in the process. Process analytical technology and multivariate models can therefore be developed in Phases 1 or 2, rather than waiting for pilot-scale data.
A data orchestration layer is a critical input for AI models, such as model-based design of experiments, which can predict process behavior and reduce the need for empirical experiments. With the power of unified data, pharmaceutical manufacturers can continue competing in an increasingly complex and dynamic marketplace.
Augmenting development and supporting scale
Standards-based, open-architecture hardware is key for manufacturers who want more flexibility, less reliance on a single vendor, and the ability to scale processes as needed. The MTP standard provides a vendor-agnostic description of equipment behavior to the control layer, standardizes how control programs are built, and lets equipment be added, removed, or reconfigured without having to rebuild automation or data systems.
In pharmaceutical manufacturing, the plug-and-produce design of MTP hardware makes it easier to introduce automation early in development. It eliminates extensive device-level programming and configuration as processes evolve. Automation engineers can build control strategies using clean, contextualized R&D data. Furthermore, because the logic is portable, teams no longer need to delay automation until processes are nearly finalized.
Abstracting module behavior and enhancing control portability streamlines the transition from lab-scale equipment to commercial production. This reduces the rush to implement automation later in development and avoids the recoding often required between pilot and production scales. Traditionally, moving from lab protocols to production-ready automation carried substantial risk of process gaps or inconsistencies. A standardized module control layer allows control strategies developed in early experiments to flow naturally into pilot and commercial systems.
Iterative recipe refinement can now occur as part of the experimental cycle rather than as a separate engineering phase. Instead of writing custom control logic for each stage, developers use a standardized control package with the same service set. The same control logic can be applied at bench scale (2 L), pilot scale (500 L), or production scale (2,000 L). Integrating automation into development in this way helps processes mature faster and more reliably, rather than treating automation as a late-stage addition.
Connected systems reduce risk
Scaling pharmaceutical products from the lab to production is a complex process that is only becoming more challenging with the introduction of novel medications. The combination of a data orchestration layer and software-abstracted controls architecture on standards-based hardware provides the insight and flexibility needed to meet these challenges. Regulatory quality monitoring is a critical part of bridging any product to market, with continuous process verification and real-time release requiring deep, consistent connectivity between equipment and analytics.
Early integration of automation establishes an audit-ready parameter lineage. The implementation of a unified data architecture and universal control layer streamlines regulatory compliance by enabling consistent collection and analysis of quality-related data, even as process equipment changes.
Unified data visibility, contextual integrity and analytical consistency are the central components needed to accelerate process development while meeting regulatory standards. At the same time, standards-based hardware adds the flexibility and interoperability required to scale those processes across different equipment and facilities. Together, these approaches allow pharmaceutical organizations to integrate automation earlier, support emerging modalities, shorten technology transfer timelines, and reduce risk during scale-up to commercial production.
